Cerebrospinal Fluid Biomarkers for Brain Tumors

Status Recruiting

Clinical Trial Summary

This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To collect cerebrospinal fluid (CSF) samples that can provide a resource to the research community for biomarker discovery in patients with gliomas. SECONDARY OBJECTIVE: I. Evaluate the feasibility of serial CSF sampling from patients with brain tumors for longitudinal evaluation of tumor biomarkers. OUTLINE: Patients undergo collection of CSF samples via lumbar puncture at least 2 times. Patients may undergo additional collection of additional CSF samples if they choose. After completion of study treatment, patients are followed up periodically. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04692324
Study type	Observational
Source	Mayo Clinic
Contact	Clinical Trials Referral Office
Phone	855-776-0015
Email	mayocliniccancerstudies@mayo.edu
Status	Recruiting
Phase
Start date	January 14, 2021
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04539574` - An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors	N/A
Completed	`NCT01474174` - Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
Completed	`NCT03071913` - Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
Recruiting	`NCT03270059` - Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System	Phase 2
Active, not recruiting	`NCT03834961` - Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia	Phase 2
Recruiting	`NCT02402244` - Project: Every Child for Younger Patients With Cancer
Completed	`NCT01217437` - Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors	Phase 2
Completed	`NCT01941758` - High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors	Phase 1
Active, not recruiting	`NCT02867592` - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	Phase 2
Recruiting	`NCT00898755` - Collecting and Storing Tissue From Young Patients With Cancer
Completed	`NCT00100802` - Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas	Phase 2
Completed	`NCT03012620` - Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types	Phase 2
Completed	`NCT01538095` - Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors	Phase 1
Withdrawn	`NCT05169151` - Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study
Recruiting	`NCT04988009` - Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology